FLAVIVACCINE project aims at delivering safe and effective protection against mosquito-borne #flavivirus infection.
Dengue, yellow fever, Zika, and West Nile viruses persist as major threats to global public health, affecting millions annually and claiming hundreds of thousands of lives. Recognising the urgency of effective interventions, the FLAVIVACCINE project seeks to offer an innovative, safe, and effective vaccine by developing and characterising a pan-flavivirus vaccine candidate.
Instead of directly targeting the virus, the project focuses on the initial infection resulting from contact with mosquito saliva. Thanks to this new approach, a single vaccine will be required to protect against multiple diseases, rather than multiple virus-specific vaccines.
Importantly, FLAVIVACCINE covers the entire research and development value chain, which may well be a valuable resource in improving pandemic preparedness and response to future threats.
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
Company Details
- Founded
- -
- Industry
- Public Health
- NAICS
-
Administration of Public Health Programs
- Keywords
- Montpellier.
Flavivaccine Questions
Flavivaccine's LinkedIn profile is https://www.linkedin.com/company/flavivaccine
Flavivaccine's industry is
Public Health
Flavivaccine's top competitors are
Mivegec,
Kitnewcare,
Pepr Prezode,
Stareso,
Inovec Project,
Sustain Consulting,
Station Stareso,
The Global Vector Hub,
Smart Era,
Women In Business And Beyond Conference.
Flavivaccine's categories are Public Health
Flavivaccine's founding year is 2024
